This clinical trial is focused on studying the treatment of a heart condition known as Patent Ductus Arteriosus (PDA) in infants with extremely low birth weight. PDA is a condition where a blood vessel called the ductus arteriosus does not close as it should after birth, which can lead to heart and lung problems. The treatment being tested in this study is Paracetamol, a medication commonly used to relieve pain and reduce fever, administered through an infusion directly into the bloodstream.

The purpose of the study is to determine if early treatment with Paracetamol can effectively reduce the risk of complications such as bleeding in the brain, a serious intestinal condition, and death before the infant is discharged from the hospital. The study will compare the effects of Paracetamol with a placebo to see which is more effective. Infants participating in the study will receive the treatment for a period of up to six days.

Throughout the study, the health of the infants will be closely monitored to assess the outcomes. The primary focus will be on the occurrence of significant complications, while secondary outcomes will include the assessment of lung development at 36 weeks and developmental progress at two years of age. This study aims to provide valuable insights into the potential benefits of using Paracetamol for treating PDA in vulnerable infants.